AGP Executive Report
Last update: 7 hours agoCBD/Medical Research: PleoPharma kicked off a pivotal Phase 3 trial of PP-01 (CAN-004) aimed at easing cannabis withdrawal symptoms in adults with cannabis use disorder, with FDA Fast Track status noted. Public Health & Youth Protection: A new study finds adolescents may find legal cannabis packaging more appealing when it uses colorful branding, cartoon-like imagery, and snack-like product photos—raising questions for how advertising rules are designed to reduce under-21 appeal. Policy & Legal: The U.S. Supreme Court unanimously ruled the federal gun ban for marijuana users is unconstitutional as applied to a person who uses cannabis regularly, limiting prosecutors’ ability to treat cannabis users as automatically too risky. Regulation/Industry: DEA rescheduling hearing participation remains contentious, with reports that only opponents were invited, while other coverage highlights ongoing inspections and compliance pressure on marijuana businesses seeking federal protections. Hemp Industry: NSW unveiled a hemp industry development plan focused on R&D, licensing improvements, supply chains, and market expansion to make hemp a “mainstream crop.” Local Access: Minnesota’s first adult-use dispensary, La Canna, opened in La Crescent, with reminders that legality can change across state lines.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Current Treatment Strategies for Dravet Syndrome]]>](https://cdn.sanity.io/images/0vv8moc6/neurolive/420733c5e203e5a36d9cd7e4fe4cfceec89ef1f7-1920x1080.png)
![<![CDATA[Current Treatment Strategies for Dravet Syndrome]]>](/images/news-fallback.svg)
